Featured Research

from universities, journals, and other organizations

Breakthrough in RSV research with drug trial

Date:
August 28, 2014
Source:
Le Bonheur Children's Hospital
Summary:
A new clinical trial of a drug was shown to safely reduce the viral load and clinical illness of healthy adult volunteers intranasally infected with respiratory syncytial virus (RSV). RSV is the most common cause of lower respiratory tract infections in young children in the United States and worldwide. It hospitalizes 125,000 children in the United States each year, and was the cause for 1.5 million outpatient visits.

The New England Journal of Medicine published research results on Aug. 21 from a clinical trial of a drug shown to safely reduce the viral load and clinical illness of healthy adult volunteers intranasally infected with respiratory syncytial virus (RSV).

Related Articles


Le Bonheur Children's Hospital and the University of Tennessee Health Science Center researcher Infectious Disease Specialist John DeVincenzo, MD, is lead author of this study.

RSV is the most common cause of lower respiratory tract infections in young children in the United States and worldwide. It hospitalizes 125,000 children in the United States each year, and was the cause for 1.5 million outpatient visits, according to the Centers for Disease Control and Prevention (CDC). DeVincenzo and his fellow researchers have been part of virtually every experimental therapeautic advancement, developmental pathway and antiviral therapy created to tackle the virus in the past 15 years.

"No effective antiviral treatment currently exists for RSV, which is the leading cause of severe childhood respiratory infections, and is extremely dangerous for babies and children," said DeVincenzo. "We were pleased that our study, for the first time, shows that the infection caused by the RSV virus can be effectively reduced after the infection has started. This is also the first time to prove that once we reduce the amount of virus in a patient, they begin to feel better very quickly. The next step is to explore clinical trials in naturally infected patients."

The challenge study of Gilead Sciences Inc.'s GS-5806, an investigational oral RSV fusion inhibitor, achieved primary and secondary endpoints of lower viral load, improvements in total mucus weight and symptom diary score compared to placebo. Volunteers in the study were given the oral drug after being infected with RSV using the experimental challenge model. The model is based on a clinical isolate from an infant hospitalized with RSV bronchiolitis which can be safely used to infect adults, and that was developed by DeVincenzo in 2007 to test proof-of-concept antivirals.


Story Source:

The above story is based on materials provided by Le Bonheur Children's Hospital. Note: Materials may be edited for content and length.


Journal Reference:

  1. John P. DeVincenzo, Richard J. Whitley, Richard L. Mackman, Cecilia Scaglioni-Weinlich, Lisa Harrison, Eric Farrell, Stephen McBride, Robert Lambkin-Williams, Robert Jordan, Yan Xin, Srini Ramanathan, Thomas O’Riordan, Sandra A. Lewis, Xiaoming Li, Seth L. Toback, Shao-Lee Lin, Jason W. Chien. Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study. New England Journal of Medicine, 2014; 371 (8): 711 DOI: 10.1056/NEJMoa1401184

Cite This Page:

Le Bonheur Children's Hospital. "Breakthrough in RSV research with drug trial." ScienceDaily. ScienceDaily, 28 August 2014. <www.sciencedaily.com/releases/2014/08/140828170015.htm>.
Le Bonheur Children's Hospital. (2014, August 28). Breakthrough in RSV research with drug trial. ScienceDaily. Retrieved January 27, 2015 from www.sciencedaily.com/releases/2014/08/140828170015.htm
Le Bonheur Children's Hospital. "Breakthrough in RSV research with drug trial." ScienceDaily. www.sciencedaily.com/releases/2014/08/140828170015.htm (accessed January 27, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, January 27, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Mistakes Should Serve a Lesson Says WHO

Ebola Mistakes Should Serve a Lesson Says WHO

AFP (Jan. 25, 2015) The World Health Organization&apos;s chief on Sunday admitted the UN agency had been caught napping on Ebola, saying it should serve a lesson to avoid similar mistakes in future. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Disneyland Measles Outbreak Spreads To 5 States

Disneyland Measles Outbreak Spreads To 5 States

Newsy (Jan. 24, 2015) Much of the Disneyland measles outbreak is being blamed on the anti-vaccination movement. The CDC encourages just about everyone get immunized. Video provided by Newsy
Powered by NewsLook.com
Growing Measles Outbreak Worries Calif. Parents

Growing Measles Outbreak Worries Calif. Parents

AP (Jan. 23, 2015) Public health officials are rushing to contain a measles outbreak that has sickened 70 people across 6 states and Mexico. The AP&apos;s Raquel Maria Dillon has more. (Jan. 23) Video provided by AP
Powered by NewsLook.com
Smart Wristband to Shock Away Bad Habits

Smart Wristband to Shock Away Bad Habits

Reuters - Innovations Video Online (Jan. 23, 2015) A Boston start-up is developing a wristband they say will help users break bad habits by jolting them with an electric shock. Ben Gruber reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins